Profilo
Mark Toomey is President at Canton Strategic Holdings, Inc. since 2025.
Former roles include Head-North America Asset Management Sales at Galaxy Digital Holdings, Inc. from 2021 to 2025, and Managing Director-Equity Institutional Derivatives at The Goldman Sachs Group, Inc. Education includes an undergraduate degree from Syracuse University and an MBA from Georgetown University.
Posizioni attive di Mark Toomey
| Società | Posizione | Inizio |
|---|---|---|
| CANTON STRATEGIC HOLDINGS, INC. | Presidente | 06/11/2025 |
Precedenti posizioni note di Mark Toomey
| Società | Posizione | Fine |
|---|---|---|
Galaxy Digital Holdings Ltd.
Galaxy Digital Holdings Ltd. Investment Banks/BrokersFinance Engages in crypto trading, lending, advisory and mining, custody platform & block chain infrastructure development and asset management business | Vendite & Marketing | 01/02/2025 |
| THE GOLDMAN SACHS GROUP, INC. | Corporate Officer/Principal | - |
Formazione di Mark Toomey
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
The Goldman Sachs Group, Inc.
The Goldman Sachs Group, Inc. Investment Banks/BrokersFinance Provides investment banking, asset, wealth management and platform services | Finance |
Syracuse University
Syracuse University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Galaxy Digital Holdings Ltd.
Galaxy Digital Holdings Ltd. Investment Banks/BrokersFinance Engages in crypto trading, lending, advisory and mining, custody platform & block chain infrastructure development and asset management business | Finance |
Tharimmune, Inc.
Tharimmune, Inc. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company that develops novel therapeutic candidates targeting ferroptosis | Health Technology |
















